AI assistant
Kairos Pharma, LTD. — Director's Dealing 2025
Nov 26, 2025
34903_dirs_2025-11-26_8cc7d43d-0bd2-48c0-94aa-d76f856838bd.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kairos Pharma, LTD. (KAPA)
CIK: 0001962011
Period of Report: 2025-09-16
Reporting Person: Keyoung Hansoo Michael (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-09-16 | COMMON STOCK | A | 10000 | $0.00 | Acquired | 10000 | Direct |
| 2025-10-08 | COMMON STOCK | A | 19084 | $0.00 | Acquired | 29084 | Direct |
Footnotes
F1: Represents 10,000 restricted stock units ("RSUs") issued to the Reporting Person under the Kairos Pharma, Ltd. 2023 Equity Incentive Plan (the "Plan"). The 10,000 RSUs were granted on September 16, 2024, in conjunction with the Issuer's initial public offering (IPO), and grant in substantially equal installments on the anniversary date of the IPO.
F2: Consists of (i) 3,334 shares of common stock and (ii) 6,666 RSUs which remain subject to vesting.
F3: Represents 19,084 RSUs) issued to the Reporting Person under the Plan. The 19,084 RSUs are scheduled to vest in full on the first anniversary of the grant date.
F4: Consists of (i) 3,334 shares of common stock and (ii) 25,750 RSUs which remain subject to vesting.